The ongoing phase I/II clinical trial is evaluating the safety, tolerability and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001 Preliminary findings include a ...
AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both switchable and allogeneic CAR-T cell therapies, today announced that it has dosed the first patient ...
The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...
CAR-T cell therapy helps some with intractable lymphoma, but those who relapse have few options. Modifying the therapy's molecular target improved response. CAR-T cell therapy, which targets a ...
SEATTLE, April 19, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced data from four ...
A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
T-cell therapy has transformed the treatment landscape for patients with relapsed or refractory large B-cell lymphoma (LBCL), ...
“CD19-directed chimeric antigen receptor (CAR)-modified T-cell therapy represents a new paradigm for the treatment of patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), however, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results